ArticlePsychopharmacology2020
Behavioral and dopamine transporter binding properties of the modafinil analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and enhancement of progressive ratio responding.
Article in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- A Series of Aryl-Substituted-(biphenyl)methyl-sulfinylmethylthiazoles as Novel and Atypical Dopamine Transporter Inhibitors.Journal of medicinal chemistry · 2026Article
- Neurochemical drivers of effort: The roles of dopamine and beyond in physical and cognitive exertion.Neuroscience and biobehavioral reviews · 2026Review
- Dopamine antagonist effects of the D2/D3 receptor partial agonist aripiprazole on effort-based choice tasks in male and female rats.Cognitive, affective & behavioral neuroscience · 2026Article
- Application of separation and configuration identification of the four tetrabenazine stereoisomers in determining their pharmacokinetics.Analytical and bioanalytical chemistry · 2025Article
- The impact of modafinil on memory and brain oxidative stress: contrasting effects of acute and chronic administration in healthy rats.Metabolic brain disease · 2025Article
- Pharmacological characterization of sex differences in the effects of dopaminergic drugs on effort-based decision making in rats.Psychopharmacology · 2024Article
- Potential therapeutics for effort-related motivational dysfunction: assessing novel atypical dopamine transport inhibitors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Article
- The Atypical Dopamine Transporter Inhibitor CE-158 Enhances Dopamine Neurotransmission in the Prefrontal Cortex of Male Rats: A Behavioral, Electrophysiological, and Microdialysis Study.The international journal of neuropsychopharmacology · 2023Article
- Effort-related effects of chronic administration of the DA DPsychopharmacology · 2023Article
- Chirality Matters: Fine-Tuning of Novel Monoamine Reuptake Inhibitors Selectivity through Manipulation of Stereochemistry.Biomolecules · 2023Article
- Effects of the atypical antipsychotic and D3/D2 dopamine partial agonist cariprazine on effort-based choice behavior: implications for modeling avolition.Psychopharmacology · 2023Article
- Low-Affinity/High-Selectivity Dopamine Transport Inhibition Sufficient to Rescue Cognitive Functions in the Aging Rat.Biomolecules · 2023Article
- A Novel and Selective Dopamine Transporter Inhibitor,Biomolecules · 2022Article
- The influence of reinforcement schedule on experience-dependent changes in motivation.Journal of the experimental analysis of behavior · 2022Article
- Effects of the dopamine depleting agent tetrabenazine on detailed temporal parameters of effort-related choice responding.Journal of the experimental analysis of behavior · 2022Article
- Cholinergic and dopaminergic-mediated motivated behavior in healthy states and in substance use and mood disorders.Journal of the experimental analysis of behavior · 2022Review
- The Novel Analogue of Modafinil CE-158 Protects Social Memory against Interference and Triggers the Release of Dopamine in the Nucleus Accumbens of Mice.Biomolecules · 2022Article
- Increased elasticity of sucrose demand during hyperdopaminergic states in rats.Psychopharmacology · 2022Article
- Vigor, Effort-Related Aspects of Motivation and Anhedonia.Current topics in behavioral neurosciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 4 countries.
Funding
Abstract
rationaleAtypical dopamine (DA) transport blockers such as modafinil and its analogs may be useful for treating motivational symptoms of depression and other disorders. Previous research has shown that the DA depleting agent tetrabenazine can reliably induce motivational deficits in rats, as evidenced by a shift towards a low-effort bias in effort-based choice tasks. This is consistent with human studies showing that people with major depression show a bias towards low-effort activities.
objectivesRecent studies demonstrated that the atypical DA transport (DAT) inhibitor (S)-CE-123 reversed tetrabenazine-induced motivational deficits, increased progressive ratio (PROG) lever pressing, and increased extracellular DA in the nucleus accumbens. In the present studies, a recently synthesized modafinil analog, (S, S)-CE-158, was assessed in a series of neurochemical and behavioral studies in rats.
results(S, S)-CE-158 demonstrated the ability to reverse the effort-related effects of tetrabenazine and increase selection of high-effort PROG lever pressing in rats tested on PROG/chow feeding choice task. (S, S)-CE-158 showed a high selectivity for inhibiting DAT compared with other monoamine transporters, and systemic administration of (S, S)-CE-158 increased extracellular DA in the nucleus accumbens during the behaviorally active time course, which is consistent with the effects of (S)-CE-123 and other DAT inhibitors that enhance high-effort responding.
conclusionsThese studies provide an initial neurochemical characterization of a novel atypical DAT inhibitor, and demonstrate that this compound is active in models of effort-related choice. This research could contribute to the development of novel compounds for the treatment of motivational dysfunctions in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.